Galmed now has a commercial-stage medical device generating revenue in Europe, diversifying away from pure drug development risk. Monitor Q3 2027 for first earnout payments and the pace of CG-100 adoption in Germany (OPS code). The $17.5M equity financing threshold for earnout acceleration is a key catalyst to watch — if Galmed raises that amount, the full $2.0M earnout becomes immediately payable, which would be a positive signal for the combined entity's trajectory.
Price Chart
Executive Summary
Galmed Pharmaceuticals consummated the acquisition of Colospan Ltd. on June 22, 2026, paying $3.3M in cash plus up to $2.0M in performance-based earnout consideration. The deal was restructured from the original terms to eliminate the issuance of $2.0M in Galmed ordinary shares at closing, replacing it with an additional $800K cash payment and a single-digit percentage earnout on net sales revenues beginning Q3 2027. Galmed gains CG-100, a CE-marked colorectal anastomosis protection device already generating revenue in Europe, with strong clinical data showing 90% stoma avoidance and 0% mortality.
Key Facts
- Galmed consummated the acquisition of Colospan Ltd. on June 22, 2026 for $3.3M cash plus up to $2.0M in performance-based earnout consideration.
- The deal was restructured to eliminate the issuance of $2.0M in Galmed ordinary shares at closing, replacing it with an additional $800K cash payment and a single-digit percentage earnout on net sales revenues.
- CG-100 is a CE-marked (MDR) intraluminal bypass device for colorectal anastomosis protection, already generating revenue in Europe with a dedicated OPS code in Germany.
- Clinical data from 97 patients across 4 trials showed 90% stoma avoidance, 0% mortality, 3% anastomotic leak rate, and 0% device migration.
- Galmed plans to invest at least $6.0M over 24 months post-closing to expand Colospan's European commercial activities.
- The earnout is capped at $2.0M, with 7% on net sales between $5M-$12M and 9% above $12M, commencing Q3 2027.
- Galmed had $15.6M cash as of March 31, 2026, and the all-cash deal avoids immediate dilution to existing shareholders.
Financial Impact
Total consideration of $3.3M cash plus up to $2.0M earnout ($5.3M max). Galmed had $15.6M cash as of March 31, 2026. Pro forma combined cash as of Dec 31, 2025 would be $1.245M. Goodwill and intangible assets of $4.9M recorded.
Risk Factors
- Galmed had only $15.6M cash as of March 31, 2026, and the pro forma combined cash position as of Dec 31, 2025 was just $1.245M, indicating significant cash burn ahead.
- The earnout is contingent on commercial success of CG-100 in Europe, which faces market adoption and reimbursement risks.
- Galmed's accumulated deficit was $210.8M as of Dec 31, 2025, and the company has no approved drug products generating revenue.
- The acquisition adds $4.9M in goodwill and intangible assets to a company with a $5M market cap, creating significant impairment risk if CG-100 fails to gain traction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-029478 |
| Exhibit: ex99-1.htm | 0001493152-26-029478 |
| Exhibit: ex99-2.htm | 0001493152-26-029478 |
| Document: form6-k.htm | 0001493152-26-029478 |
| Document: 0001493152-26-029478-index-headers.html | 0001493152-26-029478 |
| Document: 0001493152-26-029478-index.html | 0001493152-26-029478 |
| Document: 0001493152-26-029478.txt | 0001493152-26-029478 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 6-K | $4.63 $3.63 | ▼ −21.71% | ▼ −21.37% | — |
Sep 4, 2026 7w ago | EFFECT | $3.88 $4.63 | ▼ −19.33% | ▼ −20.54% | — |
Sep 3, 2026 7w ago | 6-K | $3.88 $4.63 | ▲ +19.33% | ▲ +20.54% | — |
Sep 2, 2026 7w ago | 6-K | $3.92 $4.63 | ▲ +18.11% | ▲ +19.26% | — |
Aug 19, 2026 9w ago | 6-K | $4.77 $4.33 | ▼ −9.22% | ▼ −8.84% | — |
Aug 17, 2026 10w ago | 6-K | $0.5134 | awaiting T+5 | — | — |
Jul 28, 2026 12w ago | 6-K | $0.5340 $0.5754 | ▲ +7.75% | ▲ +3.64% | — |
Jul 16, 2026 14w ago | 6-K | $0.5501 $0.5530 | ▲ +0.53% | ▲ +2.20% | — |
Jun 22, 2026 18w ago | 6-K | $0.5641 $0.5709 | ▲ +1.21% | ▲ +1.66% | — |
Jun 8, 2026 20w ago | 6-K | $0.4693 $0.6160 | ▲ +31.26% | ▲ +29.15% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers